Journal of Antimicrobial Chemotherapy, Vol 40, 779-788, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
The treatment of deep fungal infection in haematological malignancy remains
controversial due to the limited number of antifungal agents available and
problems over their spectrum and dose-limiting side- effects. Difficulties
in diagnosis mean that most treatments are begun empirically; amphotericin
B remains the drug of choice. Emerging resistance may limit the usefulness
of fluconazole and other azoles in some areas. Lipid preparations of
amphotericin B have reduced the toxicity of this agent, but some issues of
dosage and efficacy remain. Adjunctive treatments aimed at augmenting the
host response to infection may have a role to play in deep fungal
infection.
ORIGINAL ARTICLES
Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Martinez, P. Aviles, E. Jimenez, J. Caballero, and D. Gargallo-Viola Activities of Sordarins in Experimental Models of Candidiasis, Aspergillosis, and Pneumocystosis Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3389 - 3394. [Abstract] [Full Text] |
||||
